Atrium Therapeutics, Inc.
RNANasdaq
$12.15
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↓ -17.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
- CEO
- Kathleen P. Gallagher
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- atriumtherapeutics.com
Management & directors
- Gallagher Kathleen P.See Remarks
- Hoyos Rocio MartinChief Strategy Officer
- Hughes Steven GeorgeChief Medical Officer
- Kenney StephanieSee Remarks
- Winslow Brendan R.Chief Financial Officer
- Younis HusamChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
RNA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$19.6M↑ +1148.3%
Diluted EPS-$0.97↑ +120.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
No annual data.
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | $1.6M | $19.6M |
| Gross profit | — | — |
| Operating income | -$7.5M | -$17.3M |
| Net income | -$7.4M | -$16.6M |
| Diluted EPS | -$0.44 | -$0.97 |
| Operating cash flow | -$11.1M | -$31.1M |
| Free cash flow | -$11.1M | -$33.2M |
| Gross margin | — | — |
| Operating margin | -473.7% | -88.0% |
| Net margin | -473.6% | -84.7% |
Company news
Jul 20, 2026
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-20 | Kenney Stephanie· See Remarks | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-04-20 | Hughes Steven George· Chief Medical Officer | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-04-20 | Winslow Brendan R.· Chief Financial Officer | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-04-20 | Gallagher Kathleen P.· See Remarks | Award | 102,500 | $0.00 | $0.00 | filing |
| 2026-04-20 | Hoyos Rocio Martin· Chief Strategy Officer | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-04-20 | Younis Husam· Chief Scientific Officer | Award | 30,000 | $0.00 | $0.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.